AYTU
AYTU BIOPHARMA, INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.96
−3.92%Sep 22, 2026, 20:13 UTC
Aytu BioPharma reported FY2026 net revenue of $57.6 million, down 13.3% year over year, with a net loss of $14.25 million.
Source:Sep 22, 2026, 20:13 UTC
Aytu BioPharma reported Q4 2026 net revenue of $16.1 million, up 6.4% year over year, and a net loss of less than $0.1 million.
Source:Sep 16, 2026, 20:30 UTC
Aytu BioPharma announced it will report its fiscal 2026 full year and fourth quarter operational and financial results after market close on September 22, 2026, with a conference call and webcast the same day.
Source: